Navigation Links
The current state of lung cancer treatment
Date:12/11/2012

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

"We're in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure," Bunn says.

The review describes the shift from blanketing lung cancer with radiation and chemotherapy, to targeting the specific genetic mutations that cause lung cancer's many varieties. The first of these oncogenic lung cancer mutations to be exploited by a drug was the epidermal growth factor receptor (EGFR), described in 2004 and targeted by the drugs erlotinib and gefitinib. Then in 2007 the oncogenic ALK/EML4 fusion protein was described, and is now targeted by the drug crizotinib, which earned FDA approval in 2011. Drugs in the development pipeline target a handful of additional lung-cancer-causing mutations including KRAS, HER2/neu, BRAF, NRAF, and ROS.

"Pathologists used to define lung cancer as one of four types, based on its appearance," Bunn says, "but it's much more heterogenous than that. Some of these driver mutations may only be present in 1 or 2 percent of the lung cancer population, and mutations in combination may make for hundreds of species of the disease, each with its own response characteristics to targeted drugs and drug combinations."

"Whole exome sequencing shows there are about 300 mutations in the average lung cancer," Bunn says. "You may have an EGFR mutation driving the cancer, but then the other 299 mutations may help define who will do well on an EGFR inhibitor."

Bunn points out that in the lung cancer varieties whose driver oncogenes can be matched with targeted therapy, we tend to see 70-80 percent patient response as opposed to 20-30 percent response to traditiona
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
2. Triple negative breast cancer symposium highlights current advances
3. Why current strategies for fighting obesity are not working
4. Current and former smokers at risk for recurrent hepatitis post-liver transplantation
5. DMP module on heart failure: Current guidelines indicate some need for revision
6. Study suggests new way to prevent recurrent ear infections
7. Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
8. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
9. Benefit of PET or PET/CT in recurrent bowel cancer is not proven
10. Study reveals how cancer drug causes diabetic-like state
11. New drug prevents spread of human prostate cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Avid collector Andrew Hawley, from Vintage ... Eagle Auditorium Seattle concert posters. The Doors were a smash ... that year. The Seattle Eagles Auditorium concert was held on ... return to Eagles Auditorium in November the same year. The ... and comes in three colors. The poster is a split ...
(Date:9/23/2014)... 2014 What: Rutgers Presbyterian Church, ... Side that embodies the inclusion and diversity of ... and the Ecological Crisis, a public lecture led ... Emerita of Old Testament at Louisville Presbyterian Seminary. ... that lends insight into current ecological problems, including ...
(Date:9/23/2014)... Oregon survey about an exercise DVD that adds short ... elementary school students found it had a high level ... clear advantages for overly sedentary educational programs. , Called ... the Healthy Youth Program of the Linus Pauling Institute ... Brain Breaks leads children in 5-7 minute segments of ...
(Date:9/23/2014)... (September 23, 2014) Both patients and healthcare ... computed tomography (CT) colonography greatly outweighs the potential ... precipitated by false-positive diagnoses, according to a new ... journal Radiology . , Diagnostic tests used ... organ. However, when screening for colorectal cancer with ...
(Date:9/23/2014)... September 23, 2014 The ... rhinitis (AR) is highly fragmented, with the ... formulations available, under different regulatory restrictions, with ... Europe has the most developed market, with ... allergen immunotherapy tablets (AITs) all being available. ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... Increase for Small Business Owners at ... http://www.bluecrossca.com/click4biz , THOUSAND OAKS, Calif., ... fastest growing segments of California,s economy, however,many small business owners ... Blue Cross of California has just made it,easier for small ...
... vitamins and minerals does not seem to prevent the degenerative ... study published on bmj.com today. , Age related ... older people. It is caused by the progressive break down ... centre of the retina at the back of the eye. ...
... 8 Proposed,regulations that would govern who owns ... grants to for-profit organizations fail,to ensure affordable access ... for the research, the Foundation for Taxpayer and ... the people who have paid for the research ...
... Saturn, committed to health, fitness,and healthy living in communities ... health and fitness expo, held in conjunction with the ... Saturn Health and Fitness Expo, which runs Oct. 19-20 ... vendors,informational booths and groups that provide services to runners. ...
... 8 - The Washington,State Veterinary Medical Association awarded ... veterinarian with Olympia Pet,Emergency in Lacey. (Logo: ... his award in recognition of his dedication to,organized ... Washington,State University,s College of Veterinary Medicine, he has ...
... Help ... Owners Cope, SACRAMENTO, Calif., Oct. ... and language skills died last,month, his owner, scientist Irene Pepperberg, needed time ... it. Newspapers and web,sites printed his obituary and many people sent condolences. ...
Cached Medicine News:Health News:New Online Tool Makes Enrollment in Blue Cross of California Easier 2Health News:Antioxidants do not prevent degenerative eye disease 2Health News:Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn 2Health News:Saturn Shows Its Commitment to Health and Fitness by Becoming Expo Title Sponsor for The Detroit Free Press/Flagstar Marathon 2Health News:Lacey Veterinarian Awarded 2007 WSVMA Recent Graduate Award 2Health News:We Love Our Pets and Grieve When They Die 2Health News:We Love Our Pets and Grieve When They Die 3
(Date:9/23/2014)... -- Hill-Rom (NYSE: HRC ) today announced a ... WA ), the nation,s third largest not-for-profit health ... as Hill-Rom now becomes Providence Health,s sole-source provider of ... surface products. Providence Health is one ... operates 34 hospitals, 475 physician clinics, 22 long-term care ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... , Sept. 23, 2014   COTA, Inc. ... planned $7 million Series A funding round led by ... COTA is the first big data platform designed by ... cost analysis for cancer care in support of healthcare,s ... used to expand development of the COTA platform, hire ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
... DENVER--(BUSINESS WIRE)--Mar 12, 2007 - Ceragenix Pharmaceuticals,Inc. ... and dermatology, today announced that a catheter,treated ... biofilm,formation in a 21 day study., In ... soaked daily in a phosphate-suffered solution along ...
Cached Medicine Technology:Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
... Retinol binding Proetin (RBP) is small ... a complex with pre-albumin in blood but ... has been deliverd to the target cells. ... at the glomerulus and catabolized in the,renal ...
... is an enzyme immunoassay (EIA) kit for ... of the subclass of Anti-Neutrophil Cytoplasmic Antibodies ... as an aid in the diagnosis of ... associated with vasculitic disorders and glomerulonephritis (GN). ...
Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: